Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...

Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...

Such preliminary revenue results for full year 2024 are ... and cell and gene therapy companies. Forward-Looking Statements This press release contains, and our officers and representatives ...

Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with ...

FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

They had $26 million in collaboration revenue offset by $59.6 million ... may be on the fast track to an approval. Granted, cell therapy companies have shown historically that there is upside ...